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In the endoplasmic reticulum (ER) of eukaryotes, N-linked glycans are ﬁrst assembled on the lipid carrier
dolichyl pyrophosphate. The GlcNAc2Man9Glc3 oligosaccharide is transferred to selected asparagine
residues of nascent polypeptides. Defects along the biosynthetic pathway of N-glycans are associated with
severe multisystemic syndromes called congenital disorders of glycosylation. Here, we describe a deﬁciency
in the ALG12 ER a1,6-mannosyltransferase resulting in a novel type of glycosylation disorder. The severe
disease was identiﬁed in a child presenting with psychomotor retardation, hypotonia, growth retardation,
dysmorphic features and anorexia. In the patient’s ﬁbroblasts, the biosynthetic intermediate GlcNAc2Man7
oligosaccharide was detected both on the lipid carrier dolichyl pyrophosphate and on newly synthesized
glycoproteins, thus pointing to a defect in the dolichyl pyrophosphate–GlcNAc2Man7-dependent ALG12 a1,6
mannosyltransferase. Analysis of the ALG12 cDNA in the CDG patient revealed compound heterozygosity for
two point mutations that resulted in the amino acid substitutions T67M and R146Q, respectively. The impact
of these mutations on ALG12 protein function was investigated in the Saccharomyces cerevisiae alg12
glycosylation mutant by showing that the yeast ALG12 gene bearing the homologous mutations T61M and
R161Q and the human mutant ALG12 cDNA alleles failed to normalize the growth defect phenotype of the
alg12 yeast model, whereas expression of the normal ALG12 cDNA complemented the yeast mutation. The
ALG12 mannosyltransferase defect deﬁnes a new type of congenital disorder of glycosylation, designated
CDG-Ig.
INTRODUCTION
Glycosylation is a widespread post-translational modification
affecting properties and functions of proteins, and thus having a
considerable impact on numerous biological processes (1).
Accordingly, defects of glycosylation often result in develop-
mental alterations, and, when not lethal, lead to various clinical
manifestations. Within the last few years, the range of clinical
phenotypes related to glycosylation defects has been extended
to hereditary multiple exostoses (2), progeroid syndromes (3)
and muscular dystrophies (4). Hundreds of genes are involved
in the shaping of several classes of glycoconjugates (5)
suggesting a large number of potential defects along these
biosynthetic pathways leading to pathological conditions.
Alterations of N-linked glycan biosynthesis have been
grouped under the general designation congenital disorders
of glycosylation (CDG), where 10 distinct defects have been
described to date (6,7). Defects affecting the assembly of the
dolichyl pyrophosphate (DolPP)-linked GlcNAc2Man9Glc3
oligosaccharide and its subsequent transfer to nascent glyco-
proteins are classified as CDG-I, whereas alterations of N-
glycan processing represent types of CDG-II (8). Clinically,
most CDG patients present with psychomotor retardation,
hypotonia, cerebellar hypoplasia, hormonal disorders and
stroke-like episodes (9,10). However, the constellation of
symptoms often differs from case to case, hence rendering a
CDG diagnosis solely based on clinical examination a difficult
task. The detection of underglycosylated glycoproteins, such as
serum transferrin, by isoelectric focusing (11) represents a
simple diagnostic tool, although this test does not discriminate
between the different causes of CDG.
Genetic models, such as yeast and Chinese hamster ovary cell
glycosylation mutants, have been instrumental in elucidating
the molecular basis of CDG (12). Because of the conservation
in glycosylation pathways among eukaryotes, these models
provide essential clues to relate a glycosylation phenotype to its
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underlying genetic defect. In the present study, we report the
identification of a novel type of N-glycosylation disorder
characterized by a deficiency of the endoplasmic reticulum
(ER)-resident ALG12 a1,6 mannosyltransferase.
RESULTS
The patient NJ is the first child of unrelated Danish parents. He
was delivered at 34 weeks of gestation by Caesarean section
due to deterioration of the pregnancy as reflected by hemolysis,
elevated liver enzymes and a low platelet count (HELLP
syndrome). Birth weight was 1742 g, and the neonatal course
was complicated by respiratory distress, hypoglycemia,
lethargy and feeding difficulties. At age 13 months, he was
referred because of developmental delay. A computed tomo-
graphy at age 16 months showed slight widening of the frontal
subarachnoidal space. Presently, at age 21
2
years, psychomotor
retardation and hypotonia are prominent, and he is not able to
sit without support. Dysmorphic features include triangular
face, epicanthus, inverted nipples, micropenis, undescended
testes, club foot and sandal gaps. Eye examination is normal
except for a convergent squint. He has feeding problems, and
his weight and length are far below the 3% percentile.
Insulin-like growth factor (IGF)-1 and IGF-binding protein 3
are undetectable in the patient, but growth hormone stimulation
test as well as thyroid hormones are normal. Antithrombin III
(ATIII) is low (0.24 U; normal range 0.82–1.18). Alanine
aminotransferase (ALT) is normal. Notably, immunoglobulins
are repeatedly low: IgA 0.09 g/l (normal range 0.70–3.65), IgG
1.1 g/l (normal range 6.1–14.9) and IgM 0.14 g/l (normal range
0.39–2.08). He is receiving infusions of immunoglobulins at
regular intervals. He has had pneumonia three times, but no
severe infections. The karyotype is normal. Urine metabolic
screening for amino and organic acids is unremarkable.
The combination of psychomotor retardation and low ATIII
levels led to the suspicion of CDG. Isoelectric focusing of
serum transferrin showed decreased amounts of tetrasialotrans-
ferrin and increased amounts of disialo- and asialotransferrin,
thus confirming the occurrence of a glycosylation disorder
(data not shown). Phosphomannomutase and phosphomannose
isomerase activities measured in cultured fibroblasts were
normal, thus excluding CDG-Ia and -Ib (data not shown).
Analysis of lipid-linked oligosaccharides (LLO) in the patient’s
fibroblasts revealed an accumulation of the incomplete
oligosaccharide DolPP–GlcNAc2Man7 and the absence of the
mature core DolPP–GlcNAc2Man9Glc3 that is normally
detected in cells from healthy subjects (Fig. 1). The LLO
DolPP–GlcNAc2Man9Glc3 is the preferred substrate of the
oligosaccharyltransferase (OTase) complex (13), although
truncated LLO may still be transferred to proteins at low
efficiency, as shown in yeast (14).
Once on proteins, oligosaccharides are trimmed to
GlcNAc2Man9 by glucosidase-I and -II (15,16). The
GlcNAc2Man9 core usually undergoes cycles of reglucosyla-
tion and deglucosylation during the process of protein folding
(17), thereby yielding GlcNAc2Man9Glc1 besides
GlcNAc2Man9. Before leaving the ER, the oligosaccharide
core is further trimmed by a-mannosidase to GlcNAc2Man8
(18). Therefore, the normal N-linked oligosaccharide (NLO)
profile of newly synthesized proteins mainly consists of the
species GlcNAc2Man8, GlcNAc2Man9 and GlcNAc2Man9Glc1
(Fig. 2A). In contrast, the NLO profile of patient NJ fibroblasts
predominantly showed the GlcNAc2Man7 structure (Fig. 2C).
The detection of this truncated NLO in patient NJ fibroblasts
suggested that an oligosaccharide species that lacks two
mannose residues is transferred to glycoproteins in the patient’s
cells. To address the question whether DolPP–GlcNAc2Man7
or DolPP–GlcNAc2Man7Glc3 served as a substrate for the
OTase in this patient’s cells, we analyzed the NLO profile of
control and patient NJ fibroblasts in the presence of the
glucosidase inhibitor castanospermine. Whereas in control
cells castanospermine enables the detection of untrimmed
Figure 1. Lipid-linked oligosaccharide profiles. HPLC separation of [3H]man-
nose-labeled lipid-linked oligosaccharides from yeasts (A), control human
fibroblasts (B) and patient NJ fibroblasts (C). The identity of the oligo-
saccharide peaks is marked on (A) ranging from GlcNAc2Man1 (M1) to
GlcNAc2Man9Glc3 (G3). (C) shows the GlcNAc2Man7 peak accumulating in
patient NJ cells, whereas GlcNAc2Man9Glc3 is normally found in control cells,
as shown in (B).
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G l c NA c 2 M a n 9 G l c 3 ( F i g . 2 B ) , a n u n t r i m m e d
GlcNAc2Man7Glc3 species was not visible in the NLO profile
of patient NJ fibroblasts (Fig. 2D). This indicates that
GlcNAc2Man7 acts as donor substrate for the OTase complex
in patient NJ cells.
The accumulation of the LLO DolPP–GlcNAc2Man7 has
been previously documented in the Saccharomyces cerevisiae
alg12 mutant strain. This strain is characterized by a defect in
the ER-resident DolPP–GlcNAc2Man7-dependent a1,6 man-
nosyltransferase enzyme (19). The human ortholog to the yeast
ALG12 gene has not been described so far, but a BLAST
search in GenBank revealed the cDNA entry NM_024105,
which included an open reading frame encoding a protein of
488 amino acids displaying 44% similarity to the yeast ALG12
protein. Genes encoding homologous proteins were also
detected in the Drosophila melanogaster and Caenorhabditis
elegans genomes (Fig. 3). Primary sequence alignment of
putative ALG12 proteins showed highly conserved motifs, thus
pointing to regions possibly involved in the catalytic activity.
The overall identity was 32–42% between the animal sequences
and 24–26% between all the sequences.
The NM_024105 cDNA was amplified from control and
patient NJ fibroblasts and directly sequenced. We detected
compound heterozygosity for two point mutations, 200C>T and
437G>A, in the patient-derived cDNA. These two mutations
introduced the amino acid substitutions T67M and R146Q,
respectively, in the ALG12 protein sequence. These two
mutations were not found in the control cDNAs sequenced or
in the 25 expressed sequence tags retrieved from GenBank
representing fragments of the NM_024105 cDNA. The amino
acid changes introduced were at positions strictly conserved
among the eukaryotic homologous proteins analyzed (Fig. 3).
The human ALG12 gene was localized on chromosome 22
according to the working draft sequence of the clone CITF22-
1A6 (GenBank accession no. AL671710). The ALG12 gene
included 10 exons spanning 15 kb (Fig. 4A). The 200C>T and
437G>A mutations detected in patient NJ mapped to exons 3
and 4, respectively. Sequencing of these exons in parental DNA
samples indicated that the T67M mutation was of maternal origin
and the R146Q mutation was inherited from the father (Fig. 4B).
To determine whether the T67M and R146Q amino acid
substitutions affected ALG12 activity, the corresponding
Figure 2. N-linked oligosaccharide profiles. HPLC analysis of [3H]mannose-labeled N-linked oligosaccharides from control (A, B) and patient NJ (C, D) fibro-
blasts after cleavage from proteins with N-glycosidase F. The elution positions of standard oligosaccharides from GlcNAc2Man1 (M1) to GlcNAc2Man9Glc3 (G3)
are marked at the tops of the panels. In (A) and (C), cells were metabolically labeled for 1 h at 37C. In (B) and (D), cells were treated with the glucosidase inhibitor
castanospermine (250mM) for 2 h prior to metabolic labeling and extraction of N-linked oligosaccharides.
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changes (T61M and R161Q) were introduced in the
S. cerevisiae ALG12 locus. As Dalg12 strains display no
obvious growth phenotype, the effect of alg12 mutant alleles
was investigated in a Dalg12wbp1–2 strain. This strain shows
ALG12-dependent growth at 23C on full medium (YPD)
containing low amounts of hygromycin B (Fig. 5A). This
aminoglycoside antibiotic is known to be more potent against
many yeast glycosylation mutants (20).
As opposed to the wild-type gene, the mutant ALG12[T61M]
gene failed to complement this growth defect. The R161Q
mutation had a weaker effect on the integrity of the ALG12
protein than did the T61M mutation, since growth of
Dalg12wbp1–2 yeasts was restored by expression of
ALG12[R161Q] (Fig. 5A). The double mutant T61M/R161Q
had the same phenotype as the T61M mutant. We also assessed
the glycosylation status of the vacuolar glycoprotein carboxy-
peptidase Y (CPY) in Dalg12 yeasts transformed with alg12
mutant alleles. Although CPY is only mildly hypoglycosylated
in Dalg12 mutant strains, its mobility is increased owing to
truncated oligosaccharides transferred to protein (Fig. 5B)
(19). Transformation with the wild-type yeast ALG12 gene
restored a normal CPY glycosylation profile, but trans-
formation with the mutant ALG12[T61M] DNA did not. As
observed with the growth phenotype of Dalg12wbp1–2
yeast, the mutation R161Q only slightly affected ALG12
function, since the glycosylation of CPY was nearly normal
(Fig. 5B).
We expressed the NM_024105 human ALG12 cDNA under
the control of the GPD promoter in Dalg12wbp1–2 yeasts. As
shown in Figure 6, growth of Dalg12wbp1–2 yeasts was
restored by expression of this cDNA, thus establishing the
function of the corresponding protein. Importantly, the two
mutant ALG12 alleles found in the CDG patient NJ, namely
ALG12[T67M] and ALG12[R146Q], did very weakly restore
growth to the levels reached with the normal human
ALG12 cDNA. This analysis confirmed the direct relation
between these ALG12 mutations and the strongly reduced
activity of the encoded mannosyltransferase. In conjunction
with the identical phenotype observed both in patient NJ cells
and alg12 mutant yeast cells, namely the accumulation of
incompletely assembled LLO, we postulate a novel type of
CDG, specifically called CDG-Ig, that is due to a deficiency in
the ALG12 locus.
DISCUSSION
The present study defines a novel genetic disease in humans by
identifying a defect at the ALG12 mannosyltransferase locus as
cause of a glycosylation disorder in a patient presenting with
psychomotor retardation, hypotonia and various dysmorphic
features. The ALG12 defect was characterized by an
accumulation of the LLO DolPP–GlcNAc2Man7 oligosacchar-
ide in the ER. Because this LLO is a poor substrate for the
OTase complex, several N-glycosylation sites of glycoproteins
remained unoccupied. It is noteworthy that the failure to detect
the mature oligosaccharide GlcNAc2Man9Glc3, either as an
LLO or an NLO, indicates that the mutations detected in patient
NJ inactivate ALG12 activity. Thus, this CDG case represents
the first occurrence of a complete block along the LLO
biosynthetic pathway identified in humans. In fact, in all cases
of CDG-I analyzed so far, a significant portion of NLO have
been shown to be derived from the mature LLO DolPP–
GlcNAc2Man9Glc3 (21–24) (C.E. Grubenmann and C.G. Frank,
unpublished data).
The accumulation of DolPP–GlcNAc2Man7 observed in
ALG12-deficient fibroblasts indicates that, as in yeast, this
oligosaccharide is not a suitable substrate for the ALG6
glucosyltransferase, which transfers Glc via an a1,3 linkage to
the terminal mannose of the a1,2-mannose branch on DolPP–
GlcNAc2Man9 (25). In consequence, the OTase complex,
which recognizes the three terminal Glc residues on oligosac-
charides, will only transfer the truncated GlcNAc2Man7 species
at low efficiency to nascent glycoproteins. However, as
indicated by the NLO profile of castanospermine-treated cells,
it is evident that GlcNAc2Man7 is transferred to glycoproteins
in patient NJ cells. The detection of the oligosaccharide
Figure 3. Comparison of ALG12 protein sequences. ClustalW alignment (38) of ALG12 proteins from Homo sapiens (GenBank accession no. NM_024105),
D. melanogaster (RE17513), C. elegans (NM_072670) and S. cerevisiae (NP_014427). Positions conserved in the four proteins are shaded in black and residues
conserved in three proteins are shaded in gray. The amino acid substitutions T67M and R146Q detected in patient NJ are indicated above the human sequence. The
end of the D. melanogaster predicted ALG12 protein is truncated to fit this alignment.
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GlcNAc2Man7Glc1 in the fibroblasts of patient NJ is certainly
caused by the reglucosylation of GlcNAc2Man7 catalyzed by
the ER-resident UDP–Glc glucosyltransferase enzyme involved
in the quality control of protein folding (17).
The absence of mature oligosaccharides in patient NJ cells
not only decreases the amount of N-glycan chains on proteins
but also likely affects the functions assumed by this
oligosaccharide along the secretion pathway of glycoproteins.
After transfer to proteins, N-linked oligosaccharides function
as signals in the process of protein folding (26) and for the
export of misfolded glycoproteins to the cytosol for degrada-
tion (27,28). In the latter events, it has been shown in
S. cerevisiae that the transition from GlcNAc2Man9 to
GlcNAc2Man8 favors the targeting of misfolded proteins to
the degradation pathway (29). The degradation of misfolded
proteins was especially slowed down in Dalg9 and Dalg12
yeasts, indicating that GlcNAc2Man6 and GlcNAc2Man7
lacked the signaling ability for degradation of proteins.
Figure 4. Human ALG12 gene. (A) Genomic organization of the human ALG12 gene, with exons represented as numbered boxes. Introns are indicated as solid
lines. The positions of the T67M and R146Q mutations are marked on exons 3 and 4, respectively. (B) Electropherograms of ALG12 exons 3 and 4 sequenced from
patient NJ and his parents. The 200C>T and 437G>A mutations are indicated by arrows.
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Inhibition of mannose trimming by deoxymannojirimycin also
slows down the degradation of misfolded proteins in
mammalian cells (30), indicating that mannose trimming also
functions as a degradation signal in higher eukaryotes.
Besides acting as signals in the quality control of
glycoprotein folding and in the ER-associated protein degrada-
tion response (31), N-linked oligosaccharides also function as
ligands for lectin proteins such as ERGIC53 and VIP36 (32)
involved in the intracellular transport of cargo glycoproteins. It
is reasonable to expect that the combination of under-
occupancy of N-glycosylation sites and the occurrence of
truncated GlcNAc2Man7 oligosaccharides may interfere with
the folding, intracellular trafficking and ER-elimination of
glycoproteins in patient NJ cells. Therefore, altered glycopro-
tein folding and intracellular transport may account for some of
the features identified in patient NJ. For example, the absence
or low levels of the serum glycoproteins IGF-binding protein 3,
ATIII and immunoglobulins may be related to alterations along
the secretory pathway. The availability of the ALG12-deficient
cells from patient NJ now allows us to address this eventuality
and to compare the intracellular maturation of proteins with
other types of CDG.
Figure 5. Phenotypes of ALG12 yeast mutants. (A) Growth phenotype of Dalg12wpb1–2 yeasts transformed with (1) empty pRS416 vector or with pRS416 vector
expressing (2) the normal S. cerevisiae ALG12 gene, (3) the S. cerevisiae ALG12[T61M] gene, (4) the S. cerevisiae ALG12[R161Q] gene, (5) the S. cerevisiae
ALG12[T61M,R161Q] gene or (6) the S. cerevisiae normal WBP1 gene. Yeasts were grown on YPD medium at 23C without hygromycin (left panel) and with
hygromycin at 50 mg/ml (right panel). (B) Western blot analysis of carboxypeptidase Y (CPY) in Dalg12 yeasts transformed with an empty pRS416 expression
vector (mock) or with a pRS416 vector expressing the normal S. cerevisiae ALG12 gene (WT), the S. cerevisiae ALG12[T61M] gene (T61M), the S. cerevisiae
ALG12[R161Q] gene (R161Q) or the S. cerevisiae ALG12[T61M,R161Q] gene (T61M,R161M). At the left side, the positions of normally glycosylated CPY and
of those glycoforms with four, three and two truncated oligosaccharides (CPY*, CPY*[1] and CPY*[2], respectively) are marked.
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MATERIALS AND METHODS
Cell culture
Primary fibroblasts obtained from skin biopsies were cultured
in Dulbecco’s Modified Eagle’s Medium (DMEM/F12, Gibco)
with 4.5 g/l glucose and 10% fetal calf serum (FCS).
Mannose labeling
Fibroblasts were grown to 90% confluence on 450 cm2. Before
labeling, cells were washed twice with phosphate-buffered
saline (PBS) and incubated for 90 min at 37C in 45 ml
minimal Eagle’s medium (Gibco) supplemented with 5%
dialyzed FCS (Gibco). When specified, the glucosidase
inhibitor castanospermine (Calbiochem) was added at 250 mM
to the cells 2 h prior to labeling. For labeling, 150 mCi
[3H]mannose (54.0 Ci/mmol, Amersham Bioscience) was
added to the cell medium and incubated for 1 h at 37C.
Cells were washed once with ice-cold PBS and scraped from
the plates in 10 ml of methanol/0.1 mM Tris pH 7.4 (8 : 3 v/v).
Extraction of lipid- and protein-linked oligosaccharides
Chloroform (10.9 ml) was added to the cell suspension (10 ml)
and the mixture was centrifuged at 5000g for 5 min after
thoroughly mixing by vortexing. The upper and lower phases
were removed and 3 ml chloroform/methanol/water (10 : 10 : 3
v/v/v) were added to the solid interphase. LLO were recovered
from the supernatant after vortexing and centrifugation at
5000g for 5 min. The extraction was repeated three times, and
the supernatants were pooled. The samples were dried under N2
at 37C, and the dried LLOs were hydrolyzed and prepared as
described previously (33). NLO were recovered from the solid
pellet of the LLO extraction after drying under N2 at 37
C.
Proteins were solubilized and denatured in 200 ml 0.5% SDS/
2% b-mercaptoethanol at 100C for 10 min. Oligosaccharides
were cleaved from proteins by digestion with 1 unit of
N-glycosidase F (Roche Diagnostics) in 300 ml of 50 mM
sodium phosphate buffer pH 7.5, 1% Nonidet-P40, 0.33%
SDS and 1.33% b-mercaptoethanol for 12 h at 37C.
Thereafter, 900 ml of cold ethanol was added, and the samples
were centrifuged for 20 min at 2600g. The supernatants were
then spun again for 30 min at 20 000g at 4C. This supernatant
was dried in a Speed-vac concentrator and resuspended in
400 ml of acetonitrile/water (7 : 3 v/v), passed through a
0.45 mm filter (Millipore) and subjected to HPLC.
HPLC analysis of oligosaccharides
[3H]Mannose-labeled oligosaccharide samples were separated
on a 250 mm 4.6 mm LC-NH2 aminopropyl column
(Supelco), equipped with an LC-NH2 guard column, as
described previously (33).
RT–PCR
Total RNA was extracted from fibroblasts (2 107) using Tri-
reagent (Sigma), following the instructions of the manufacturer.
The human ALG12 cDNA was prepared from 4 mg of total
Figure 6. Complementation of Dalg12wbp1–2 yeasts with human ALG12 cDNAs. YG843 transformants were spotted in 10-fold dilutions on YPD plates and
incubated at 23C for 6 days in the absence (left panel) or presence of 30mg/ml hygromycin (right panel). Transformation was done with the pRS416 vector alone
(mock), the pRS416 vector expressing the S. cerevisiae ALG12 gene (ScALG12), the p426GPD vector expressing the human ALG12 cDNA (HsALG12) or the
mutant HsALG12 cDNAs (HsALG12[T67M] and HsALG12[R146Q]), and with the YEp352 vector expressing the WBP1 gene (39) (WBP1).
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RNA using the primer 5 0-TGCCCAGTCCTTTGA-
CTTGCTTC-30 and 4 units of Omniscript reverse transcriptase
(Qiagen). The 20 ml reaction mixtures were incubated at 37C
for 2 h. The protein-coding region of the human ALG12 cDNA
was amplified by PCR from 2 ml of RT product with the primers
50-CAGTGCTAACGGCTGGTGTCTC-30 and 50-CTGGTAG-
TGATAACAGCTCCTGGA-30. The cycling conditions were
35 cycles at 94C for 45 s, 60C for 30 s and 72C for 2 min.
Primers and unincorporated nucleotides were removed with
QIAquick columns (Qiagen), and the PCR products were
sequenced (Microsynth, Balgach, Switzerland).
Genomic DNA PCR
Genomic DNA from patient NJ and his parents was isolated
from 107 fibroblasts and 5 ml of blood, respectively. The human
ALG12 gene sequence was included in the chromosome
22 clone CITF22-1A6 (GenBank accession no. AL671710).
ALG12 exons 3 and 4 were amplified with the primers 50-AAG
TGGAGGAGAGCTTCAAC-3 0, 5 0-GCAGGCAAGAC
TAACAGACA-30 and 50-GCTGGCATTGCAGCAGCATA-30,
50-GCTGTTGGCCAGGAAGTGTG-30, respectively, for 35
cycles at 94C for 45 s, 55C for 30 s and 72C for 1 min.
The PCR products were sequenced (Microsynth, Balgach,
Switzerland) after removal of primers and unincorporated
nucleotides.
Plasmid construction
Human ALG12 cDNAs were amplified from normal and CDG-
Ig patient cDNA with the primers 50-CTAAAGAATTCT
GTCTCGCACTGTTG-30 and 50-GCTTCTAGAAGACCTG
TGGCTGCTGA-30 containing EcoRI and XbaI restriction
sites, respectively, and subcloned into the same sites of
pBluescript-II KSþ (Stratagene). The human ALG12 cDNAs
were subcloned as blunted HindIII-XbaI fragments into the
SmaI site of p426GPD (34), placing them under control of the
strong glyceraldehyde-3-phosphate dehydrogenase promoter.
The homologous T61M and R161Q substitutions were
introduced into the yeast ALG12 gene by quick-change
mutagenesis (Stratagene) of pALG12 (19) using the oligo-
nucleotides 50-GGAGTAGTCCCTAGAATGTTCGTTGGTGC
TGTGATTATTGC-30 and 50-GCAATAATCACAGCACCAAC
GAACATTCTAGGGACTACTCC-30 for T61M and the oligo-
nucleotides 50-CCTCATGTTCTACAGCACTCAAACTC
TGCCTAATTTTGTCATGAC-30 and 50-GTCATGACAAAAT
TAGGCAGAGTTTGAGTGCTGTAGAACATGAGG-30 for
R161Q. The 1.2 kb Eco81I–SacI fragments from the result-
ing plasmids were subcloned into pCFZ14–416ALG12 (see
below), replacing its Eco81I–SacI fragment, to yield the
mutated forms. A second round of mutagenesis following the
same procedure was performed to combine the mutations. The
regions between the Eco81I and SacI sites of the mutated
plasmids were verified by sequencing. To create pCFZ14–
416ALG12, a single-copy plasmid with the yeast ALG12 gene,
the 2.4 kb KpnI–SacI fragment of pALG12 was subcloned into
the same sites of pRS416 (35).
Yeast strains and media
S. cerevisiae strains used in this study were derivatives of
YG840 (MATa ade2-101 ura3–52 his3D200 lys2–801
Dalg12::kanMX4) (19) or YG843 (MATa ade2–101 ade3
ura3–52 his3D200 leu2 Dalg12::kanMX4 wbp1–2) (19).
Standard yeast media and genetic techniques were used (36).
Strain YG840 and its transformants were propagated at 30C,
and strain YG843 and its transformants at 23C.
Complementation of alg12 yeast mutants
Western blotting of the carboxypeptidase Y glycoprotein was
performed as described previously (37). Hygromycin B
sensitivity of Dalg12 wbp1–2 transformants was assessed on
full medium (YPD) plates containing 30 or 50 mg/ml hygro-
mycin B (Roche Diagnostics). For the spot assay, 5 ml of serial
10-fold dilutions of YG843 transformants grown overnight in
liquid medium were spotted, starting at 5 105 cells. Plates
were incubated at a given temperature for 6 days.
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